The following contains information and content supplied by members of the Industry Allies Council. Information contained herein regarding any specific person, commercial product, or service by trade name, trademark, manufacturer or otherwise, does not constitute or imply its endorsement, recommendation, or favoring by the American Association of Diabetes Educators, its directors or employees.
Brought to you by Janssen Pharmaceuticals
Janssen Pharmaceuticals, Inc., is focused on tackling some of the world’s most burdensome diseases, concentrating on areas of unmet need, like type 2 diabetes. For decades, healthcare providers have worked to manage A1C levels in people with type 2 diabetes; however, we know these individuals sometimes need help treating the many comorbidities associated with type 2 diabetes as well.
Approximately 1 in 3 individuals with type 2 diabetes also has diabetic kidney disease. Yet 48% of people with severely reduced kidney function, but who are not on dialysis, are not aware that they have diabetic kidney disease. We hope to lower this number by raising awareness among diabetes care and education specialists and healthcare providers about the connection between type 2 diabetes and diabetic kidney disease.
Janssen was the first company to conduct a dedicated renal outcomes trial that studied type 2 diabetes and its association with kidney disease, kidney failure, and cardiovascular events. We work tirelessly with healthcare providers to help ensure they have the latest clinical data and treatment options at their disposal when outlining a treatment plan with those in their care.
We’re focused on the whole person in an effort to help healthcare providers change the trajectory of care for people with type 2 diabetes. Learn more about Janssen at janssen.com.